Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors

Cancer

Volumn 118, Issue 20, 2012, Pages 5078-5083

  Balagula, Yevgeniy ^a   Rosen, Alyx ^a   Tan, Belinda H ^a   Busam, Klaus J ^a   Pulitzer, Melissa P ^a   Motzer, Robert J ^a   Feldman, Darren R ^a   Konner, Jason A ^a   Reidy Lagunes, Diane ^a   Myskowski, Patricia L ^a   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adverse event; everolimus; mammalian target of rapamycin; rash; temsirolimus

Indexed keywords

BEVACIZUMAB; CLINDAMYCIN; CLOBETASOL; COTRIMOXAZOLE; DIPHENHYDRAMINE; DOXEPIN; DOXYCYCLINE; EVEROLIMUS; FLUOCINONIDE; HYDROXYZINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; PREDNISONE; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL SUPERINFECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; ERYTHEMA; FACE RASH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIMB DISEASE; MALE; NECK RASH; OUTCOME ASSESSMENT; PANCREATIC NEUROENDOCRINE TUMOR; PAPULE; PRIORITY JOURNAL; PRURITUS; PUSTULE; RETROSPECTIVE STUDY; SCALP PRURITUS; SKIN BIOPSY; TREATMENT DURATION; TRUNK; UTERUS CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84867337737     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27505     Document Type: Article

References (18)

1. Dancey J,. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010; 7: 209-219.
2. Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M,. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009; 4: 135-142.
3. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
4. Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME,. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. Eur J Cancer. 2012; 48: 340-346.
5. Mahe E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006; 55: 139-142.
6. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW,. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006; 17: 1227-1229.
7. Cuthbert RJ, Craig JI, Ludlam CA,. Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. Ulster Med J. 1993; 62: 95-97.
8. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E,. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010; 24: 149-156.
9. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004; 22: 2336-2347.
10. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011; 117: 5094-5102.
11. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1588-1595.
12. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1603-1610.
13. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005; 3: 599-606.
14. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005; 79: 476-482.
15. Gandhi M, Kuzel T, Lacouture M,. Eosinophilic rash secondary to temsirolimus [serial online]. Clin Genitourin Cancer. 2009; 7: E34-E36.
16. Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z,. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog. 2003; 38: 25-32.
17. Kim S, Wong P, Coulombe PA,. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature. 2006; 441: 362-365.
18. Perez-Soler R, Saltz L,. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005; 23: 5235-5246.